Sigyn Therapeutics Inc. (OTCMKTS:SIGY) Stock Gains Momentum: Jumps 10%
Sigyn Therapeutics Inc. (OTCMKTS:SIGY) was up 10% after announcing the successful completion of its in vivo animal trial showing that Sigyn Therapy was well-tolerated and safe.
Market Stats
On Wednesday, SIGY stock gained 10% to $0.44 with more than 7.8K shares, compared to its average volume of 2.1K shares. The stock moved within a range of $0.4400 – 0.4975 after opening trading at $0.45.
Sigyn Therapeutics™ Announces Completion of Animal Studies
Sigyn Therapy is a unique blood purification technique meant for treating life-threatening inflammatory disorders such as sepsis, the main driver of hospital fatalities, by performing duties that are above the reach of medications and overcoming the constraints of current devices. The in vivo study results will be included in an Investigational Device Exemption (IDE) to be submitted to the US FDA to support the possible start of human clinical trials.
Eight pricing subjects weighing 40-45kg received Sigyn Therapy through standard dialysis machines that use standard blood-tubing sets of up to six hours. Overall, the therapy was good tolerable in all subjects without any adverse events in the treated sample. Most importantly, treatment safety, including serum chemistries, hematological measurements, and hemodynamic parameters, were stable in all subjects. Therefore, SIGY is worth watching.
Key Quote
“Based on its demonstrated ability to extract pathogens, toxins and inflammatory mediators from blood plasma, we believe Sigyn Therapy may hold promise for addressing significant unmet needs in global health that remain beyond the reach of drugs,” stated Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “The successful completion of our animal study marks the achievement of a major milestone for our company as we take another step toward fulfilling our clinical vision for saving lives.”
